In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)
Conclusions ASP9521 is a potent, selective, orally bioavailable AKR1C3 inhibitor.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Hormones | Investigational New Drugs | Oral Cancer | Prostate Cancer | Study